We have developed an orally bioavailable small molecule platform that allows targeting of endothelial cells in brain and retina for cell selective intracellular delivery of pharmacological conjugates. We are in the process of doing proof of principle experiments to demonstrate in vivo tolerability and specificity, PK and ideal route of administration for an initial indication in wet/dry AMD. We are also investigating potential applications in other ocular and neurological disorders.